Review of the Anticholinergics for the Treatment of Overactive Bladder: 2009 Update.
- Author:
Seung June OH
1
Author Information
1. Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. sjo@snu.ac.kr
- Publication Type:Review
- Keywords:
Overactive bladder;
Muscarinic antagonists
- MeSH:
Cholinergic Antagonists*;
Drug Therapy;
Muscarinic Antagonists;
Nocturia;
Quality of Life;
Urinary Bladder, Overactive*;
Solifenacin Succinate;
Tolterodine Tartrate
- From:Journal of the Korean Continence Society
2009;13(1):7-22
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Overactive bladder is a chronic condition defined by bothersome urgency with or without urgency incontinence, usually associated with daytime frequency and nocturia. The treatment of this condition is to control bothersome urinary symptoms and is therefore to improve quality of life. The Korean Continence Society published the overactive bladder guideline in 2007, which suggested the mainstay of management is behavioral therapy and antimuscarinic pharmacotherapy. With growing awareness toward overactive bladder and quality of life, clinical information regarding antimuscarinic agents should be updated. There are several agents with good level of evidence and good grade of recommendation. Newer antimuscarinic agents are available or will be available in near future. The pharmacological properties, efficacy and tolerability of oxybutynin, trospium, propiverine, tolterodine, darifenacin, solifenacin, fesoterodine and imidafenacin are reviewed and discussed here. The results of major clinical studies are summarized.
